Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 agonist weight-loss drug Wegovy, cutting the drug's price in half to $ ...

Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes ... Ozempic for diabetes and Wegovy for obesity – for the first ...

The analysis explored data from the trial to determine the association of tirzepatide treatment with changes in thigh muscle volume, muscle volume z-score and muscle fat infiltration in people ...

1 In 2017, Novo Nordisk introduced semaglutide (Ozempic), a long-acting GLP-1 RA used to improve glycemic control, and later approved in 2021 under the brand name Wegovy as an injection to promote ...

Medical news, education and information for physicians and health care professionals, presented by specialty and topic. From Healio and the Wyanoke Group.